Chemocentryx, Inc.

Mark M Gleason

Penglie Zhang

Yibin Zeng

Lianfa Li

Jay Patrick Powers

Wei Yu Chen

Manmohan Reddy Leleti

Pingchen Fan

Juan Carlos Jaen

Yandong Li

Andrew M K Pennell

Jeffrey P McMahon

Xi Chen

Kevin Lloyd Greenman

Yuan Xu

John J Kim Wright

Dean R Dragoli

Juan C Jaen

Junfa Fan

Wei Chen

Jeffrey P Mcmahon

Andrew M Pennell

John J Wright

Jay Powers

John Kim J Wright

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Azaindazole compounds and methods of use

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Modulators of CXCR7

Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.

Growing community of inventors

Redwood City, CA, United States of America

Mark M Gleason